Nonasthmatic eosinophilic bronchitis in an ulcerative colitis patient – a putative adverse reaction to mesalazine: A case report and review of literature

Andrei Tudor Cernomaz, Gabriela Bordeianu, Cristina Terinte, Cristina Maria Gavrilescu

Abstract

BACKGROUND
Lung and airway involvement in inflammatory bowel disease are increasingly frequently reported either as an extraintestinal manifestation or as an adverse effect of therapy.

CASE SUMMARY
We report a case of a patient with ulcerative colitis controlled under mesalazine treatment who presented with chronic cough and hemoptysis. Chest computed tomography and bronchoscopy findings supported tracheal involvement in ulcerative colitis; pathology examination demonstrated an unusual eosinophil-rich inflammatory pattern, and together with clinical data, a nonasthmatic eosinophilic bronchitis diagnosis was formulated. Full recovery was observed within days of mesalazine discontinuation.

CONCLUSION
Mesalazine-induced eosinophilic respiratory disorders have been previously reported, generally involving the lung parenchyma. To the best of our knowledge, this is the first report of mesalamine-induced eosinophilic involvement in the upper airway.

Key Words: Mesalazine; Ulcerative colitis; Hemoptysis; Bronchitis; Drug-related side effects; Case report
Respiratory involvement is sometimes reported in inflammatory bowel disease patients, either as extradigestive lesions or as therapy adverse effects. Mesalazine, a common therapeutic option in mild forms of ulcerative colitis, has been associated to eosinophilic respiratory and cardiovascular disorders. We report a patient exhibiting symptoms suggestive for nonasthmatic eosinophilic bronchitis. Available data supports the hypothesis of a previously unreported mesalazine adverse effect.

Citation: Cernomaz AT, Bordeianu G, Terinte C, Gavrilescu CM. Nonasthmatic eosinophilic bronchitis in an ulcerative colitis patient – a putative adverse reaction to mesalazine: A case report and review of literature. World J Clin Cases 2020; 8(18): 4162-4168

INTRODUCTION
Mesalazine is a 5-aminosalicylic acid derivative recommended for the long-term management of mild and moderate forms of inflammatory bowel disease. The adequate efficacy and safety profile of this drug explain its frequent use.

Mesalazine respiratory toxicity is uncommon and incompletely understood. Relevant available data consist mainly of case reports concerning mesalazine-induced eosinophilic pneumonia, nonspecific interstitial pneumonia (NSIP) and cryptogenic organizing pneumonia (COP).

We report the case of an ulcerative colitis (UC) patient who developed chronic nonspecific respiratory symptoms with mesalazine treatment; available data support the idea of a previously unreported respiratory side effect.

CASE PRESENTATION

Chief complaints
A 40-year-old woman was referred to our tertiary level pneumology unit for an irritating chronic cough sometimes accompanied by mild hemoptysis (up to 20 mL fresh blood/d).

History of present illness
These symptoms had been present for the last six months; no clear triggers or aggravating factors were identified.

History of past illness
She was a nonsmoker, had no previous pulmonary diseases and had no significant occupational exposure. The patient had a six-year history of moderate UC managed mainly by dietary advice and cycles of mesalazine.

Six months prior to admission in our hospital, she had been evaluated for digestive complaints: Cramping periumbilical pain, loose bowel movements and rectorrhagia; colonoscopy was performed, and pathological data confirmed an UC flare up that prompted mesalazine treatment (Eudragit coated tablets 6 g daily, same formula that the patient previously used). The digestive complaints subsided, but respiratory symptoms (dry cough that aggravated during the night, sometimes with mild hemoptysis) seemed to develop two weeks following admission to the gastroenterology department. An infectious etiology was presumed by her general practitioner, although the chest radiographs and sputum cultures were negative; symptomatology persisted under two courses of broad spectrum antibiotics (amoxicillin/clavulanate 2 g daily, 10 d, clarithromycin 500 mg daily, 7 d). After approximately one month the patient was referred to a secondary pneumology unit; atopic reaction (to an unidentified agent) and cough variant asthma were considered and patient received antihistamine (levocetirizine 5 mg daily, 14 d) and inhaled beta 2 mimetic and corticoid treatment (beclometasone/formoterol 100/6 μg every 12 h, ongoing). As no significant clinical improvement was noted after three months, the
patient was referred to our tertiary pneumology unit for further evaluation.

**Physical examination**
Physical examination was unremarkable. Lung function tests were within the normal range.

**Laboratory examinations**
The patient had mild eosinophilia (780 elements/mmc, 10.3%); no other significant hematological or biochemical anomalies were found.

**Imaging examinations**
Computed tomography of the chest demonstrated irregular circumferential thickening of the subglottic region and upper trachea, a diffusely enlarged thyroid and sparse tracheal nodules (Figure 1); the distal airways, lung parenchyma and mediastinal structures were normal.

**Pathologic evaluation**
Flexible bronchoscopy showed viscous tracheal secretions and edematous, friable, nodular mucosa from the larynx to main bronchi; no clear hemorrhagic spots were identified; serial biopsies were performed (tracheal, carina and main bronchi). Bronchial fluid bacteriology tests were negative; cytology showed a neutrophilic/eosinophilic inflammatory profile. The biopsy specimens showed deep mucosal ulcerations with granulation tissue, abundant inflammatory infiltrate containing numerous eosinophils, epithelial healing with squamous metaplasia and regenerative atypia (Figure 2).

**FINAL DIAGNOSIS**
Available clinical and pathology data were compatible with mesalazine-triggered nonasthmatic eosinophilic bronchitis (NAEB).

**TREATMENT**
We opted for mesalazine discontinuation and continued inhaled corticoids/long-acting beta mimetics (beclometasone/formoterol 100/6 μg every 12 h).

**OUTCOME AND FOLLOW-UP**
Cough and hemoptysis subsided after one week following mesalazine discontinuation. Inhaled beclometasone/formoterol was stopped after one month and patient was discharged to gastroenterology services for UC management with a mesalazine avoidance recommendation. Patient remained symptom free at the six-month follow up being managed only on dietary advice.

**DISCUSSION**
Respiratory manifestations of inflammatory bowel disease are well recognized; the incidence is considered to be low, although underdiagnosis may be a problem[^1].

Both the airways and lung parenchyma may be involved; chronic bronchitis, bronchiectasis, and COP are typical associations[^2-7], tracheal and large airway involvement is rarely mentioned. As available data are limited to case reports, less than 50 total to the best of our knowledge, it is difficult to compile a clear archetypal picture of upper airway involvement in UC; nevertheless, some common elements have emerged from the available literature[^8]. Tracheal lesions seem to affect mainly nonsmoking young females with UC during a stable phase of the disease (even after colectomy[^9]). The symptoms/signs are nonspecific and of variable intensity, including hoarseness, chronic cough, sputum production, and in severe cases, upper airway obstructive syndrome[^10]. Bronchoscopy demonstrated various patterns: Erythema, edema, attenuation or disappearance of the stripes of the tracheal cartilage, and
**Figure 1** Upper airway mucosa lesions. A: Axial computed tomography (CT) (lung window) showing circumferential irregular thickening of the tracheal wall - subglottic region; B: Axial CT (lung window) demonstrating the presence of a tracheal mucosa nodule-carina level.

**Figure 2** Hematoxylin-eosin stained tracheal mucosal biopsies demonstrating the presence of eosinophil-rich infiltrate. A: Magnification 25 ×; B: Magnification 100 ×; C: Magnification 200 ×; D: Magnification 400 ×.

whitish granular lesions, mucosal folds and nodules, which were sometimes described as papillomatous.

Pathology shows nonspecific findings (some findings may coexist): Inflammatory infiltrate dominated by lymphocytes or neutrophils; some authors specifically noted the relative absence of eosinophils; squamous metaplasia; ulceration; and granulation tissue with fibrin rich exudate and re-epithelialization; granuloma formation is possible, thus prompting the differential diagnosis with sarcoidosis, tuberculosis, amyloidosis and granulomatosis with polyangiitis. Corticoids, either inhaled or systemic, and other immunomodulator agents are considered effective, but scarring and severe tracheal stenosis may develop.

Our case shares some features with the reported cases of UC with tracheal involvement but differs from the pathological point of view because of the presence of the eosinophil-rich infiltrate.

This prompted us to formulate three hypotheses: A rare, previously undescribed inflammatory pattern of the upper airway in UC, mesalamine adverse effects, or other causes of eosinophilic tracheo-bronchitis. Clinical data seemed to support the
mesalamine hypothesis – the symptoms appeared shortly after treatment initiation and promptly disappeared following drug cessation.

To assess causality, both the Naranjo algorithm and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were applied using available data. The Naranjo algorithm returned a score of 6, corresponding to a probable adverse drug reaction, especially considering the following: Symptoms onset after the suspected drug was given, improvement after drug discontinuation, no credible alternative causes, and confirmed by objective evidence.

Similarly, using the WHO-UMC causality assessment scale, we considered an adverse drug reaction as probable or likely, as the clinical and pathological findings seemed to have a reasonable relationship with drug intake, no other explanations were found, and the response to withdrawal was clear.

A drug rechallenge would have provided valuable data but was deemed unethical as long as the patient was symptom free and alternative medication was available for the pharmacological management of UC in case of a flare up.

Mesalazine is currently considered a first-choice drug for mild and moderate UC; its use is rarely associated with respiratory adverse reactions, with the notable exception of rhinitis/pharyngitis, which is considered common. Mesalazine allergic reactions and eosinophil-related disorders, such as eosinophilic pneumonia, have been described but are considered extremely rare. Furthermore, according to the available sparse data, available mesalamine respiratory adverse events typically involve the lung parenchyma and distal airways; COP, NSIP, and eosinophilic alveolitis have been reported, with potential serious consequences, while the large airways seem to be spared. Drug discontinuation, corticoids and other immune modulators have been reported as generally effective approaches in such cases.

Mesalazine respiratory toxicity is not completely understood, and various mechanisms have been postulated, including both immune (dose independent) and direct (dose dependent) mechanisms. There are data suggesting that various formulations of mesalazine have different safety profiles, while the excipients used may play a role, an alternative explanation may rest on pharmacodynamic differences between formulations. We did not consider excipients or pharmacodynamic differences to be relevant for our patient, as she previously used the same mesalazine formulation from the same producer; furthermore, the six-month treatment duration makes a manufacturing issue extremely improbable.

It is also worth mentioning that mesalazine adverse reactions may develop after variable exposure periods ranging from a few days to more than five years.

An attempt to systematize the clinical manifestations was made: The presence of chronic cough for more than 8 wk, normal lung function tests, lack of response to bronchodilators, eosinophil-rich bronchial aspirate and eosinophil infiltration of the tracheal and bronchial mucosa were compatible with a positive diagnosis of either NAEB or atopic asthma. The lack of response to corticoids and antihistaminic agents tips the balance towards a NAEB diagnosis - mesalazine discontinuation and the use of low-dose inhaled corticoids were in accordance with relevant clinical practice guidelines.

NAEB is usually linked to exogenous exposure, and multiple culprits have been reported: Isocyanates, acrylates, welding fumes, resin hardeners, formaldehyde, latex, and flour. The pathogenesis of NAEB, while not completely understood, shares mechanisms with asthma, one notable difference is the increased prostaglandin D2 concentration in the sputum of NAEB patients. Prostaglandin D2 is involved in UC healing processes, and its synthesis in the colonic mucosa is upregulated during long-term remission. The biological effects of PD2 are mediated by its receptors: D-type prostanooid, which has an anti-inflammatory role; and CRTH2, which has a proinflammatory role and is known to be involved in eosinophilic activation (and actually used as a therapeutic target in asthma).

Considering this, we might infer that in our case, NAEB was the consequence of extraintestinal UC involvement, with tracheal inflammation being modulated by mesalazine towards an eosinophilic pattern. Such a hypothesis might explain both the tracheal localization and evolution on drug discontinuation, but the limited available data do not allow for further substantiation.

**CONCLUSION**

To the best of our knowledge, this is the first report of nonasthmatic eosinophilic bronchitis as a probable type B adverse reaction to mesalazine in a UC patient.
Both respiratory involvement in inflammatory bowel disease and mesalazine adverse effects, while infrequent, may significantly alter quality of life and lead to serious and potentially lethal complications; UC patients with chronic respiratory symptoms should be thoroughly investigated, and the data should be carefully considered.

Physicians confronted with such a case are recommended to perform invasive approaches as pathology data may prove useful in guiding management even in the absence of a clear-cut diagnosis.

REFERENCES

1. van Rheenen PF, Aloiz M, Biron IA, Carlsten K, Cooney R, Cucchiara S, Cullen G, Escher JC, Kierkus J, Lindsay JO, Rom E, Russell RK, Sieczkowska-Golub J, Harbord M. European Crohn's and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease. J CrohnsColitis 2017; 11: 1032-1038 [PMID: 28158494 DOI: 10.1093/ecco-jcc/jjx010]

2. Foster RA, Zander DS, Mereng PJ, Valentine JF. Mesalazine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis 2003; 9: 308-315 [PMID: 14559114 DOI: 10.1017/S00054725-03039900-00004]

3. Larsen S, Bendzken K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010; 42: 97-114 [PMID: 20166813 DOI: 10.3109/07853890903559724]

4. Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007; 131: 524-532 [PMID: 17296657 DOI: 10.1378/chest.06-1074]

5. Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J 2000; 15: 5-10 [PMID: 10678613 DOI: 10.1183/09031936.00.15100500]

6. Papanikolaou I, Kagouridis K, Papiris SA. Patterns of airway involvement in inflammatory bowel diseases. World J Gastroenterol 2014; 5: 560-569 [PMID: 25409999 DOI: 10.4292/wjg.v5.i4.560]

7. Chiu K, Wright JL. Large and Small Airway Disease Related to Inflammatory Bowel Disease. Arch Pathol Lab Med 2017; 141: 470-473 [PMID: 28234576 DOI: 10.5858/arpa.2016-0188-RS]

8. Majewski S, Piotrowski W. Pulmonary manifestations of inflammatory bowel disease. Arch Med Sci 2015; 11: 1179-1188 [PMID: 26780878 DOI: 10.5114/ams.2015.56343]

9. Park S, Park J, Kim IK, Kim JY, Hur SC, Lee JH, Jung JW, Lee J. Tracheal Involvement in Crohn Disease: the First Case in Korea. Clin Endosc 2016; 49: 202-206 [PMID: 26879553 DOI: 10.5468/cc.2015.050]

10. Lamblin C, Copin MC, Billaut C, Marli R, Tacq V, Riviere O, Wallaert B. Acute respiratory failure due to tracheobronchial involvement in Crohn's disease. Eur Respir J 1996; 9: 2176-2178 [PMID: 8904886 DOI: 10.1183/09031936.96.09102176]

11. Betancourt SL, Palacio D, Jimenez CA, Martinez S, Marom EM. Thoracic manifestations of inflammatory bowel disease. AJR Am J Roentgenol 2011; 197: W452-W456 [PMID: 21862772 DOI: 10.2214/ajr.10.5353]

12. Javia S, Agrawal A, Patell R, Jasdanwala S. Tracheobronchitis as an extraintestinal manifestation of ulcerative colitis. BMJ Case Rep 2014; [PMID: 25326560 DOI: 10.1136/bcr-2014-205328]

13. Horgan J, Mulrennan S, D’Orsogna L, McLean-Tooke A. Tracheobronchitis in ulcerative colitis: a case report of therapeutic response with infliximab and review of the literature. BMC Gastroenterol 2019; 19: 171 [PMID: 31675916 DOI: 10.1186/s12876-019-1691-0]

14. Farkas ZC, Keshishyan S, Chakinala RC, Fraser S, Saeed F, Yusuf Y, Shilagani C, Bodin R, Harris K, Aronow WS. Tracheobronchitis with stridor in a patient with ulcerative colitis. Ann Transl Med 2018; 6: 445 [PMID: 30596073 DOI: 10.21037/atm.2018.10.47]

15. Price SE, Frampton SJ, Coochlo T, Fowler DJ, Holdens S, Beatie RM, Ismail-Koch H, Burgess A. Crohn’s supraglottitis - The presenting feature of otherwise asymptomatic systemic disease. Int J Pediatr Otorhinolaryngol Extra 2013; 8: 131-136 [DOI: 10.1016/j.pedex.2013.08.004]

16. Kinebuchi S, Ohashi K, Nakada T, Moriyama H, Yoshizawa H, Kobayashi O, Suzuki E, Gejyo F. Tracheobronchitis associated with Crohn's disease improved on inhaled corticotherapy. Intern Med 2004; 43: 829-834 [PMID: 15497519 DOI: 10.2169/internalmedicine.43.829]

17. Kuzniar T, Steelman C, Brugère O, Groussard O, Mal H, Mellot F, Pariente R, Malolepszy J, Fournier M. Severe tracheobronchial stenosis in a patient with Crohn's disease. Eur Respir J 2000; 15: 209-212 [PMID: 10676848 DOI: 10.1034/j.1399-3003.2000.15x28.x]

18. Zhang Y, Luo L, Wang X, Liu X, Wang X, Ding Y. Mesalazine-induced eosinophilic pneumonia with bone marrow infiltration: a case report and literature review. Ther Clin Risk Manag 2016; 12: 975-981 [PMID: 27366075 DOI: 10.2147/TRCM.S107012]

19. Kotsiou OS, Gourgouliamis KI. A case report of mesalazine-induced lung injury: A reversible drug side effect. Respir Med Case Rep 2019; 27: 100865 [PMID: 31193970 DOI: 10.1016/j.rmcr.2019.100865]

20. Moeser A, Pietz MW, Hagel S, Kroege I, Stallmach A. Lung disease and ulcerative colitis—mesalazine-induced bronchiolitis obliterans with organizing pneumonia or pulmonary manifestation of inflammatory bowel disease? Z Gastroenterol 2015; 53: 1091-1098 [PMID: 26367026 DOI: 10.1055/s-0041-103377]

21. Gapat A, Gulati S. Mesalazine induced eosinophilic pneumonia. Respir Med Case Rep 2017; 21: 116-117 [PMID: 28458997 DOI: 10.1016/j.rmcr.2017.04.010]

22. Ferrusquia J, Pérez-Martínez I, Gómez de la Torre R, Fernández-Almira ML, de Francisco R, Rodrigo L, Riestra S. Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity. World J Gastroenterol 2015; 21: 4069-4077 [PMID: 25852295 DOI: 10.3748/wjg.v21.i13.4069]

23. Collins HW, Frye JW. Interstitial Lung Disease in a 70-Year-Old Man with Ulcerative Colitis. ACG Case Rep J 2018; 5: e28 [PMID: 29670924 DOI: 10.14309/crj.2018.28]
Cernomaz AT et al. Mesalazine induced nonasthmatic eosinophilic bronchitis

24 Abraham A, Karakurum A. Acute respiratory failure secondary to mesalamine-induced interstitial pneumonitis. BMJ Case Rep 2013; 2013 [PMID: 23964037 DOI: 10.1136/bcr-2013-009834]
25 Jain N, Petru C, Bandyopadhyay T. Mesalamine lung toxicity. Conn Med 2010; 74: 265-267 [PMID: 20599416]
26 Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 2012; 13: 39 [PMID: 22651223 DOI: 10.1186/1465-9921-13-39]
27 Sossai P, Cappellato MG, Stefani S. Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine. Mt Sinai J Med 2001; 68: 389-395 [PMID: 11687867]
28 Xie C, Quan R, Hong F, Zou K, Yan W, Fu Y. The culprit of mesalamine intolerance: case series and literature review. BMC Gastroenterol 2019; 19: 138 [PMID: 31366329 DOI: 10.1186/s12876-019-1049-2]
29 Ye B, van Langenberg DR. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? World J Gastrointest Pharmacol Ther 2015; 6: 137-144 [PMID: 26558148 DOI: 10.4292/wjgpt.v6.i4.137]
30 Muzzi A, Ciani F, Bianchini D, Festini G, Volpe C. Adverse pulmonary effects of mesalamine. Chest 1995; 108: 1181 [PMID: 7555145 DOI: 10.1378/chest.108.4.1181-a]
31 Harris A, Esvaran S, Bosworth B, Gambarn-Gelwan M, Scherl EJ. Mesalamine-induced Pneumonitis and Serum Sickness-like Reaction. Gastroenterol Hepatol (N Y) 2007; 3: 875-877 [PMID: 21960800]
32 Gibson PG, Dolovich J, Denburg J, Ramsdale EH, Hargreave FE. Chronic cough: eosinophilic bronchitis without asthma. Lancet 1989; 1: 1346-1348 [PMID: 26558148 DOI: 10.1378/chest.108.4.1181-a]
33 Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 2002; 57: 178-182 [PMID: 11828051 DOI: 10.1136/thorax.57.2.178]
34 Kasahara KFM. Eosinophilic Bronchial Disorders Presenting Chronic Cough: Atopic Cough, Cough Variant Asthma and Non-Asthmatic Eosinophilic Bronchitis. J Genet Syndr Gene Ther 2014; 5: 217 [DOJ: 10.4172/2157-7412.1000217]
35 Brightling CE. Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 116S-121S [PMID: 16428700 DOI: 10.1378/chest.129.1_suppl.116S]
36 Di Stefano F, Di Giampaolo L, Verna N, Di Gioacchino M. Occupational eosinophilic bronchitis in a foundry worker exposed to isocyanate and a baker exposed to flour. Thorax 2007; 62: 368-370 [PMID: 16055615 DOI: 10.1136/thx.2005.045666]
37 Yildiz T, Dülger S. Non-astmatic Eosinophilic Bronchitis. Turk Thorac J 2018; 19: 41-45 [PMID: 29404185 DOI: 10.5152/TurkThoracJ.2017.17017]
38 Brightling CE, Ward R, Woltermann G, Bradding P, Sheller JR, Dworski R, Pavorid ID. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med 2000; 162: 878-882 [PMID: 10988099 DOI: 10.1164/ajrccm.162.3.9909064]
39 Vog L, Ferraz JG, Panaccone R, Beck PL, Wallace JL. A pro-resolution mediator, prostaglandin D2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci USA 2010; 107: 12023-12027 [PMID: 20547854 DOI: 10.1073/pnas.1004982107]
40 Sturm EM, Radnai B, Jandl K, Stanciic A, Parzmair GP, Higenauer C, Kump P, Wenzl H, Petritsch W, Pieber TR, Schuligoi R, Marsche G, Ferreiros N, Heinemann A, Schicho R. Opposing roles of prostaglandin D2 receptors in ulcerative colitis. J Immunol 2014; 193: 827-839 [PMID: 24929001 DOI: 10.4049/jimmunol.1303484]
